129 related articles for article (PubMed ID: 27012210)
21. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
22. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
23. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
[TBL] [Abstract][Full Text] [Related]
24. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.
Ferrari-Amorotti G; Chiodoni C; Shen F; Cattelani S; Soliera AR; Manzotti G; Grisendi G; Dominici M; Rivasi F; Colombo MP; Fatatis A; Calabretta B
Neoplasia; 2014 Dec; 16(12):1047-58. PubMed ID: 25499218
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
26. [Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells].
Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
Ai Zheng; 2006 Aug; 25(8):967-73. PubMed ID: 16965676
[TBL] [Abstract][Full Text] [Related]
27. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
28. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.
Badia E; Duchesne MJ; Semlali A; Fuentes M; Giamarchi C; Richard-Foy H; Nicolas JC; Pons M
Cancer Res; 2000 Aug; 60(15):4130-8. PubMed ID: 10945620
[TBL] [Abstract][Full Text] [Related]
29. Effective electrochemotherapy with curcumin in MDA-MB-231-human, triple negative breast cancer cells: A global proteomics study.
Mittal L; Aryal UK; Camarillo IG; Raman V; Sundararajan R
Bioelectrochemistry; 2020 Feb; 131():107350. PubMed ID: 31518962
[TBL] [Abstract][Full Text] [Related]
30. H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells.
Pandolfi L; Bellini M; Vanna R; Morasso C; Zago A; Carcano S; Avvakumova S; Bertolini JA; Rizzuto MA; Colombo M; Prosperi D
Biomacromolecules; 2017 Oct; 18(10):3318-3330. PubMed ID: 28886247
[TBL] [Abstract][Full Text] [Related]
31. PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.
Yang T; Ren C; Qiao P; Han X; Wang L; Lv S; Sun Y; Liu Z; Du Y; Yu Z
Oncogene; 2018 Nov; 37(45):5997-6009. PubMed ID: 29985480
[TBL] [Abstract][Full Text] [Related]
32. Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells.
Baghi N; Bakhshinejad B; Keshavarz R; Babashah S; Sadeghizadeh M
Gene; 2018 Sep; 670():55-62. PubMed ID: 29753810
[TBL] [Abstract][Full Text] [Related]
33. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
34. High motility of triple-negative breast cancer cells is due to repression of plakoglobin gene by metastasis modulator protein SLUG.
Bailey CK; Mittal MK; Misra S; Chaudhuri G
J Biol Chem; 2012 Jun; 287(23):19472-86. PubMed ID: 22496452
[TBL] [Abstract][Full Text] [Related]
35. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance.
Schoenlein PV; Periyasamy-Thandavan S; Samaddar JS; Jackson WH; Barrett JT
Autophagy; 2009 Apr; 5(3):400-3. PubMed ID: 19221464
[TBL] [Abstract][Full Text] [Related]
36. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.
Li NY; Weber CE; Mi Z; Wai PY; Cuevas BD; Kuo PC
J Am Coll Surg; 2013 Jul; 217(1):17-26; discussion 26. PubMed ID: 23619316
[TBL] [Abstract][Full Text] [Related]
37. Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.
Wolfson B; Padget MR; Schlom J; Hodge JW
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244306
[TBL] [Abstract][Full Text] [Related]
38. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells.
Madeo A; Vinciguerra M; Lappano R; Galgani M; Gasperi-Campani A; Maggiolini M; Musti AM
Oncogene; 2010 Feb; 29(7):978-91. PubMed ID: 19935718
[TBL] [Abstract][Full Text] [Related]
39. Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
Lin HY; Han HW; Wang YS; He DL; Sun WX; Feng L; Wen ZL; Yang MK; Lu GH; Wang XM; Qi JL; Yang YH
Chin Med; 2020; 15():23. PubMed ID: 32175001
[TBL] [Abstract][Full Text] [Related]
40. FOXA1 Induces E-Cadherin Expression at the Protein Level via Suppression of Slug in Epithelial Breast Cancer Cells.
Anzai E; Hirata K; Shibazaki M; Yamada C; Morii M; Honda T; Yamaguchi N; Yamaguchi N
Biol Pharm Bull; 2017; 40(9):1483-1489. PubMed ID: 28867731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
